Not Yet RecruitingPhase 1ACTRN12607000363482

The Role of Androgens in Angiogenesis and Endothelial Progenitor Cell Mobilisation

The Effect of Androgen Therapy on Endothelial Progenitor Cell Mobilisation and Function in Healthy Men


Sponsor

Dr. Martin Ng, Royal Prince Alfred Hospital.

Enrollment

40 participants

Start Date

Aug 1, 2007

Study Type

Interventional

Conditions

Summary

Increasing evidence suggests that sex steroids, including male sex hormones (androgens), may an important role in regulating processes critical to cardiovascular health and disease. The capacity for the body to grow new blood vessels (“angiogenesis”) in response to occluded arteries is a critical reparative process in the cardiovascular response to injury. Recently, endothelial progenitor cells (EPC) derived from bone marrow have been implicated in new blood vessel formation and in cardiac repair in cardiovascular disease. While androgens have long been known to stimulate stem cell proliferation, their effects in EPCs are unknown. The current study will investigate the effects of androgen therapy in young and older men on EPC mobilisation and function. By better understanding the role of androgens in cardiovascular health and disease, our study will substantially strengthen the evidence base on which to guide the increasing efforts to exploit the wider therapeutic benefits of androgens, particularly in the context of the rapidly growing population of aging men.


Eligibility

Sex: MalesMin Age: 35 YearssMax Age: 60 Yearss

Plain Language Summary

Simplified for easier understanding

This study investigates the Role of Androgens in Angiogenesis and Endothelial Progenitor Cell Mobilisation. It is open to men only, aged 35 to 60. People who are people with diabetes cannot take part. If you are interested, you may need to attend study visits and follow the research team's instructions.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Intervention: Testosterone Undecanoate (1000mg) one intramuscular injection on randomisation and one injection at 6 weeks only. The participants will return for follow-up assessment at week 12 (1 m

Intervention: Testosterone Undecanoate (1000mg) one intramuscular injection on randomisation and one injection at 6 weeks only. The participants will return for follow-up assessment at week 12 (1 month post final injection) and at week 16.


View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000363482